Medical Management of Charcot Foot
Immediate knee-high immobilization with a total contact cast is the cornerstone of medical therapy for acute Charcot foot and must be initiated at the first clinical suspicion, even before imaging confirmation 1, 2.
Immediate Mechanical Offloading (Primary Treatment)
The hierarchy of offloading devices is critical and should be followed in order of preference:
- Total contact cast (TCC) is the first-line device, providing optimal immobilization and pressure redistribution across the entire foot and ankle 2, 3.
- Knee-high walker rendered non-removable is the second choice when TCC is not feasible—achieve non-removability by encasing the walker with cast material or secure tie-wraps 2.
- Removable knee-high device is the third choice, reserved only for patients who cannot tolerate non-removable devices; the major limitation is non-adherence, which significantly increases risk of disease progression 2.
- Never use below-ankle devices (surgical shoes, post-operative sandals, custom molded shoes) as they fail to immobilize the midfoot and ankle joints where Charcot most commonly occurs 2.
Adjunctive Weight-Bearing Reduction
- Prescribe assistive devices including crutches, walkers, or wheelchairs to further minimize weight-bearing on the affected limb during the acute phase 2.
- The goal is complete or near-complete non-weight-bearing until clinical and radiographic signs of remission are achieved 3.
Pharmacological Therapy (Adjunctive, Not Primary)
- Intranasal calcitonin salmon may be considered as adjunctive therapy, though evidence is limited 4.
- Bisphosphonates (intravenous and oral) have demonstrated reduction in bone turnover markers but have not shown significant effect on temperature reduction or clear clinical benefit; current evidence is weak and does not support routine use 5.
- Antiresorptive agents should not replace mechanical offloading, which remains the definitive treatment 5.
Monitoring for Disease Remission
Immobilization must continue until all three criteria are met:
- Temperature normalization: Serial infrared thermometry showing temperature difference between affected and contralateral foot reduced to < 2°C 2.
- Clinical resolution: Complete resolution of edema and erythema 1, 2.
- Radiographic healing: Plain radiographs or MRI demonstrating fracture consolidation and bone remodeling 2, 3.
Do not rely on soft tissue edema alone to determine remission; a combined approach using temperature, clinical examination, and imaging is mandatory 1, 2.
Duration of Immobilization
- Continue TCC or non-removable device for the entire duration of the acute phase, typically 3-6 months or longer until all remission criteria are met 3, 6.
- Serial temperature measurements and clinical assessments should guide the frequency of follow-up appointments 1.
- MRI can be used to assess bone marrow edema resolution, though routine follow-up MRI may prolong treatment duration without clear benefit on long-term outcomes 7.
Transition to Chronic Phase Management
After achieving remission:
- Immediately transition to customized footwear with depth insoles or ankle-foot orthoses to prevent reactivation and ulcer development 3, 6.
- Below-knee customized devices should be used when significant deformity or joint instability persists 2.
- Never allow a gap between ending immobilization and starting protective footwear, as this increases risk of reactivation 3.
Critical Pitfalls to Avoid
- Delaying offloading until imaging confirmation leads to progressive deformity, ulceration, and increased amputation risk 2, 4.
- Using removable devices without confirmed patient adherence compromises treatment efficacy 2.
- Premature discontinuation of immobilization before all three remission criteria are met results in reactivation 2, 3.
- Relying on laboratory markers (CRP, ESR, WBC, alkaline phosphatase) to diagnose or exclude Charcot is not recommended as they do not aid in diagnosis 1, 2.